Cargando…
Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines
Imatinib mesylate (IM) is a tyrosine kinase inhibitor, which inhibits phosphorylation of downstream proteins involved in BCR-ABL signal transduction. It has proved beneficial in treating patients with chronic myeloid leukaemia (CML). In addition, IM demonstrates activity against malignant cells expr...
Autores principales: | Uziel, O, Fenig, E, Nordenberg, J, Beery, E, Reshef, H, Sandbank, J, Birenbaum, M, Bakhanashvili, M, Yerushalmi, R, Luria, D, Lahav, M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361771/ https://www.ncbi.nlm.nih.gov/pubmed/15870711 http://dx.doi.org/10.1038/sj.bjc.6602592 |
Ejemplares similares
-
Differential downregulation of telomerase activity by bortezomib in multiple myeloma cells-multiple regulatory pathways in vitro and ex vivo
por: Weiss, C, et al.
Publicado: (2012) -
The effect of Bortezomib and Rapamycin on Telomerase Activity in Mantle Cell Lymphoma
por: Uziel, Orit, et al.
Publicado: (2014) -
The Effects of Proteasome Inhibitors on Telomerase Activity and Regulation in Multiple Myeloma Cells
por: Shalem-Cohavi, Naama, et al.
Publicado: (2019) -
Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
por: Dufresne, A, et al.
Publicado: (2010) -
Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™)
por: Cho, Ah Young, et al.
Publicado: (2011)